Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

Figure 5

ELISA test for MMP2 and VEGF quantification on osteosarcoma cell line supernatants. The concentration of secreted MMP2 (a) and VEGF (B) on 48 h conditioned supernatants of untreated (Black bars) and 5 μM sorafenib treated (white bars) OS cells was shown per 106 cells as Mean +/- standard deviation (Y error bars) of 2 different experiments in triplicate. a, p < 0.05 versus untreated cells; b, p < 0.05 versus sorafenib.

Back to article page